How much funding has Merus raised?

Merus has raised $156.0M in total funding, most recently a Series C round.

Who are Merus's investors?

Merus's investors include Genmab, Novo Holdings A/S, Sofinnova Partners, LSP Life Sciences Partners, Novartis Venture Fund, Rock Springs Capital.

Where is Merus headquartered?

Merus is headquartered in Utrecht, Netherlands.

What industry is Merus in?

Merus operates in Biotech, Healthcare.

Merus

Acquired

Closing in on cancer

Public · Utrecht, Netherlands · Founded 2003 · $156.0M raised

Biotech

Healthcare

Headquarters: Utrecht
Employees: 201–500
Founded: 2003
Business Model: B2B
Website: merus.nl

Total Funding: $156.0M
Last Round: $83.0M Series CAug 2015
Rounds: 5
Type: Public

About

Merus N.V. is a clinical-stage oncology company headquartered in Utrecht, Netherlands, that develops innovative multispecific antibody therapeutics for cancer patients using its proprietary Multiclonics® platform. Founded in June 2003, Merus engineers full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics®) antibodies that simultaneously engage multiple cancer targets, enabling novel mechanisms of action not achievable with conventional monoclonal antibodies. Its lead asset, petosemtamab, targets EGFR and LGR5 and is advancing in Phase 3 trials for recurrent or metastatic head and neck cancer. The company also maintains a US office in Cambridge, Massachusetts, and was acquired by Genmab in 2025, joining a global leader in antibody therapeutics.

Summary

Merus is a Biotech company based in Utrecht, Netherlands, founded in 2003. It has raised $156.0M in total across 5 rounds, most recently a $83.0M Series C round in Aug 2015. Investors include Genmab, Novo Holdings A/S and Sofinnova Partners.